Viewing Study NCT01273532


Ignite Creation Date: 2025-12-24 @ 9:34 PM
Ignite Modification Date: 2025-12-31 @ 10:21 PM
Study NCT ID: NCT01273532
Status: COMPLETED
Last Update Posted: 2012-03-13
First Post: 2011-01-07
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 50-mg Tablets Relative to One 100-mg Tablet
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module